Effect of empagliflozin on cardiovascular death in subgroups by age: results from EMPA-REG OUTCOME

被引：0
|
作者：
Ridderstrale, M. [1 ]
Fitchett, D. [2 ]
Kis, S. Giljanovic [3 ]
Woerle, H. J. [4 ]
Mattheus, M. [4 ]
Zinman, B. [5 ]
Inzucchi, S. [6 ]
机构：
[1] Steno Diabet Ctr, Gentofte, Denmark
[2] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[3] Eli Lilly Suisse SA, Representat Off, Zagreb, Croatia
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany
[5] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Mt Sinai Hosp, Div Endocrinol, Toronto, ON, Canada
[6] Yale Univ, Endocrinol Sect, Sch Med, New Haven, CT USA
来源：
EUROPEAN HEART JOURNAL | 2016年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5803
引用
收藏
页码：1192 / 1192
页数：1
相关论文
共 50 条
  • [31] Effect of Qualifying Atherosclerotic Cardiovascular Disease Diagnosis Proximity on Cardiovascular Risk and Benefit of Empagliflozin in the EMPA-REG OUTCOME Trial
    Odutayo, Ayodele
    Zinman, Bernard
    Wanner, Christoph
    Zwiener, Isabella
    Lund, Soren S.
    Hantel, Stefan
    Fitchett, David
    Udell, Jacob A.
    CJC OPEN, 2024, 6 (07) : 868 - 875
  • [32] Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Khunti, Kamlesh
    Fitchett, David H.
    Wanner, Christoph
    Mattheus, Michaela
    George, Jyothis T.
    Ofstad, Anne Pernille
    Zinman, Bernard
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (09): : 3025 - 3035
  • [33] Effect of Empagliflozin on Total Events of Myocardial Infarctions by Subtype in the EMPA-REG OUTCOME Trial
    Fitchett, David H.
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Anker, Stefan D.
    Pocock, Stuart
    Kaspers, Stefan
    George, Jyothis T.
    Johansen, Odd Erik
    Jamal, Waheed
    Mattheus, Michaela
    Vedin, Ola
    Hantel, Stefan
    Lund, Soren S.
    CIRCULATION, 2020, 142
  • [34] Effect of empagliflozin when added to insulin in patients with type 2 diabetes and high cardiovascular (CV) risk: results from EMPA-REG OUTCOME
    Jurisic-Erzen, D.
    Johansen, O.
    George, J.
    Mattheus, M.
    Zinman, B.
    Inzucchi, S.
    DIABETOLOGIA, 2016, 59 : S349 - S349
  • [35] How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Zinman, Bernard
    Fitchett, David
    Wanner, Christoph
    Ferrannini, Ele
    Schumacher, Martin
    Schmoor, Claudia
    Ohneberg, Kristin
    Johansen, Odd Erik
    George, Jyothis T.
    Hantel, Stefan
    Bluhmki, Erich
    Lachin, John M.
    DIABETES CARE, 2018, 41 (02) : 356 - 363
  • [36] Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
    Inzucchi, Silvio E.
    Wanner, Christoph
    Hehnke, Uwe
    Zwiener, Isabella
    Kaspers, Stefan
    Clark, Douglas
    George, Jyothis T.
    Zinman, Bernard
    DIABETES CARE, 2019, 42 (04) : E53 - E55
  • [37] Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial
    Monteiro, Pedro
    Bergenstal, Richard M.
    Toural, Elvira
    Inzucchi, Silvio
    Zinman, Bernard
    Hantel, Stefan
    Kis, Sanja Giljanovic
    Kaspers, Stefan
    George, Jyothis T.
    Fitchett, David
    AGE AND AGEING, 2019, 48 (06) : 859 - 866
  • [38] Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
    Scheen, A. J.
    DIABETES & METABOLISM, 2016, 42 (04) : 224 - 233
  • [39] Understanding EMPA-REG OUTCOME
    Gilbert, Richard E.
    Connelly, Kim A.
    LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (12): : 930 - 931
  • [40] Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-REG OUTCOME trial explained by conventional cardiovascular risk factors?
    Coleman, R. L.
    Gray, A.
    Broedl, U. C.
    Fitchett, D.
    George, J. T.
    Woerle, H. J.
    Zinman, B.
    Holman, R. R.
    DIABETIC MEDICINE, 2017, 34 : 23 - 23
12345